Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status.

Claudia OmariniStefania BettelliCecilia CapreraSamantha ManfrediniMonica BarboliniLuca MoscettiChrystel IscaAngela TossElena BarbieriLaura CortesiShaniko KaleciAntonino MaioranaGiovanni TazzioliStefano CascinuFederico Piacentini

Published in: Journal of cancer research and clinical oncology (2019)

According to HR status, HER2 + tumors express different pathways profiles: the overexpression of PI3K, MAPK and NOTCH pathways in HER2+/HR- group could justify different survival outcomes and treatment sensitivity. The identification of tumor driver pathways may be a useful instrument for individualized pathway-directed therapies. Further clinical implications are warranted.

Keyphrases

early breast cancer
cell proliferation
poor prognosis
transcription factor
combination therapy
binding protein